Furthermore, because AD and MCI-AD patients share a metabolic course with Aβ peptides, there is an associated increase in soluble APP concentrations, which makes it challenging to correlate decreased synthesis to lower Aβ42 concentrations [49, 52]. Here, APP is linked to Alzheimer disease.